Fei Shih

Fei Shih is a seasoned pharmaceutical executive with extensive experience in clinical development and leadership roles across various organizations. Currently serving as Vice President and Global Asset Lead for IPN60130 at Ipsen since October 2020, Fei previously held the position of Executive Medical Director at Clementia Pharmaceuticals Inc., focusing on transformative medicines for pediatric and orphan diseases. Notable prior roles include Senior Director at Momenta Pharmaceuticals, where Fei led clinical development of biosimilars, and Director at Biogen, overseeing clinical development and serving as the clinical lead for BIIB023 in lupus nephritis. Additional experience at Pfizer includes directing clinical affairs and contributing to the development of Tofacitinib for psoriatic arthritis and pediatric psoriasis, as well as working on translational medicine initiatives. Fei Shih holds a Bachelor of Arts in Biochemical Sciences from Harvard University and an MD PhD in Medicine and Immunology from the University of Pennsylvania.